Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy
Noll L Campbell,1–4 Todd C Skaar,5 Anthony J Perkins,2 Sujuan Gao,2,3,6 Lang Li,7 Babar A Khan,2,3,5 Malaz A Boustani2,3,81College of Pharmacy, Purdue University, West Lafayette, 2Indiana University Center for Aging Research, 3Regenstrief Institute, 4Department of Pharmacy, Eskenazi Health...
Guardado en:
Autores principales: | Campbell NL, Skaar TC, Perkins AJ, Gao S, Li L, Khan BA, Boustani MA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/257933c644f449adbc06d1d4e6a09824 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review
por: Ruangritchankul S, et al.
Publicado: (2021) -
Active anti-acetylcholinesterase component of secondary metabolites produced by the endophytic fungi of Huperzia serrata
por: Wang,Zhejian, et al.
Publicado: (2015) -
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
por: Kandiah N, et al.
Publicado: (2017) -
Pharmacogenomic Testing and Patient Perception Inform Pain Pharmacotherapy
por: Feng-Hua Loh, et al.
Publicado: (2021) -
Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
por: Wade AG, et al.
Publicado: (2014)